U.S. License Holder:
Novartis Pharms. Corp.
Date of License:
October-07-2019
Last Update:
Sep-30-2024
FDA-Approved Indications
BEOVU (brolucizumab-dbll) is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of:
Neovascular (Wet) Age-Related Macular Degeneration (AMD);
Diabetic Macular Edema (DME).